Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±ºñ´ëÁõ ȯÀÚ¿¡¼­ °æ¿äµµÀü¸³¼±ÀýÁ¦¼ú°ú °æ¿äµµÀü¸³¼±Àü±â±âÈ­¼úÀÇ ºñ±³ A Comparison of Transurethral Resection of Prostate and Transurethral Electrovaporization of Prostate in Benign Prostatic Hyperplasia

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 5È£ p.594 ~ 600
±èÇÐÇö, ÀÓä»ó,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇÐÇö (  ) 
ÀüºÏ´ëÇб³

ÀÓä»ó (  ) 
ÀüºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

°á·Ð
Àü¸³¼±ºñ´ëÁõ ȯÀÚ¸¦ ´ë»óÀ¸·Î °æ¿äµµÀü¸³¼±ÀýÁ¦¼ú°ú °æ¿äµµÀü¸³¼±Àü±â±âÈ­¼úÀÇ È¿°ú¿Í
¾ÈÀü¼º¿¡ ´ëÇØ ¼ú ÈÄ 12°³¿ù±îÁö ÃßÀû °üÂûÇÑ °á°ú ¾ç±º ¸ðµÎ¿¡¼­ ±¹Á¦ Àü¸³¼±Áõ»óÁ¡¼ö, ÃÖ
°í¿ä¼ÓÀÇ À¯ÀÇÇÑ °³¼±À» º¸¿´°í, ¾ç±º ¸ðµÎ¿¡¼­ ½É°¢ÇÑ ÇÕº´ÁõÀº ¾ø¾úÀ¸¸ç, ¼úÁß ¶Ç´Â ¼úÈÄ
ÀÌȯÀ², ƯÈ÷ ÃâÇ÷Àº °æ¿äµµÀü¸³¼±Àü±â±âÈ­¼ú±º¿¡¼­ ´õ Àû¾úÀ¸¸ç µµ´¢°ü À¯Ä¡ ±â°£, ÀÔ¿ø±â
°£µµ ÁÙÀÏ ¼ö ÀÖ¾ú´Ù. º» ¿¬±¸ÀÇ °á°ú¿¡ ºñÃß¾î º¼ ¶§ Àúħ½ÀÀûÀÎ ¼ö¼úÄ¡·á¸¦ ¿øÇÏ´Â Àü¸³
¼±ºñ´ëÁõ ȯÀÚÀÇ °æ¿ì °æ¿äµµÀü¸²¼±Àü±â±âÈ­¼úÀÌ ÀüÅëÀûÀÎ °æ¿äµµÀü¸³¼±ÀýÁ¦¼úÀ» ´ëüÇÒ ¼ö
ÀÖ´Â ÁÁÀº ¼ö¼ú¹ýÀ̶ó »ý°¢µÈ´Ù. ¾ÕÀ¸·Î °æ¿äµµÀü¸³¼±Àü±â±âÈ­¼úÀÇ ¿µ¿ªÀ» ´õ ³ÐÈ÷±â À§ÇØ
¼­´Â È¿°ú¿Í ¾ÈÀü¼º ¸é¿¡¼­ ¸¹Àº ¿¬±¸°¡ ÀÌ·ç¾îÁø °æ¿äµµÀü¸³¼±ÀýÁ¦¼úó·³ ¸¹Àº Áõ·Ê¿¡ ´ë
ÇÑ Àå±âÀûÀÎ ÃßÀû°üÂû°ú Áö¼ÓÀûÀÎ ¼ö¼úÀåºñÀÇ °³¹ßÀÌ ÇÊ¿äÇÒ °ÍÀÌ´Ù.
#ÃÊ·Ï#
Purpose : To evaluate comparative efficacy and safety of transurethral resection of the
prostate(TURP) and electrovaporization(TVP), we reviewed the records of sixty patients
with benign prostatic hyperplasia(BPH) who underwent TURP or TVP.
Materials and Methods : Sixty symptomatic patients formed the subject of this study.
Preoperative and postoperative international prostate symptom score(I-PSS), uroflow-
metry, operative details, and complications were recorded in each patient. Baseline, 6 and
12 months follow-up data were used for analyses.
Results : We compared 30 men treated by TURP with 30 men treated by TVP from
March 1996 to July 1997. There were no significant difference in the preoperative patient
characteristics including age, symptom duration, I-PSS, peak urinary flow rate and
prostate volume on TRUS between the two groups. In the TURP group, mean I-PSS
decreased from 20.5 at preoperation to 7.9 and 6.4, and mean peak urinary flow rate
increased from 7.5§¢/sec at preoperation to 15.6§¢/sec and 17.3§¢/sec at 6 and 12
months, respectively(p<0.01). In the TVP group, mean I-PSS decreased from 18.2 at
preoperation to 8.0 and 6.8, and mean peak urinary flow rate increased from 8.4§¢/sec at
preoperation to 15.6§¢/sec and 15.7§¢/sec at 6 and 12 months, respectively(p<0.01). The
changes of hemoglobin(2.1¡¾0.7 versus 0.9¡¾0.2g/§£) and hematocrit(4.9¡¾1.2 versus 2.4¡¾
0.7%) were greater with TURP than with TVP(p<0.01). There was no significant
difference in operation time(42.6¡¾19.5 versus 40.5¡¾21.7minutes, p=0.69). Catheterization
time(4.5¡¾1.6 versus 2.9¡¾1.3days) and hospitalization time(5.9¡¾1.9 versus 4.2¡¾1.7days)
were longer with TURP than with TVP(p<0.01).
Conclusions : TURP and TVP were effective surgical procedures to treat patients with
symptomatic BPH. Both significantly improved subjective symptoms and increased peak
urinary flow late. Morbidity, catheterization time, and hospital stays were less with
electrovaporization. With this results, we conclude that TVP is an erective and safe
alternative surgical modality for the treatment of BPH.

Transurethral resection of the prostate; Transurethral electrovaporization of the prostate; Benign prostatic hyperplasia;

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS